Suzhou Xiankuo Biological Technology

Suzhou Xiankuo Biological Technology is a clinical-stage biotechnology company based in Suzhou, China, focused on discovering and developing innovative small molecule therapeutics for oncology. The company leverages its expertise in the RAS/MAPK signaling pathway and targeted protein degradation to address challenging cancer targets previously considered undruggable. Its lead candidate, XK-001, is a potent and selective SOS1 inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors, particularly those harboring KRAS mutations. Xiankuo is supported by a team of experienced scientists and a consortium of leading healthcare investors, aiming to deliver precision medicines to patients worldwide. The company maintains a robust internal R&D engine focused on overcoming drug resistance in various solid tumor types.